{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T15:03:24Z","timestamp":1774451004326,"version":"3.50.1"},"reference-count":14,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; The efficacy of topical steroids in bullous pemphigoid (BP) was assessed by prospective therapeutic trials. Systemic corticosteroids and immunosuppressant agents are indicated in situations of failure or relapses. &lt;i&gt;Objectives:&lt;\/i&gt; To report our experience in the management of BP outside therapeutic trials focusing on the outcome of the patients at 6 and 12 months, compliance and follow-up difficulties. &lt;i&gt;Methods:&lt;\/i&gt; Monocenter retrospective study with collection of clinical, therapeutic and follow-up data after 6 and 12 months. &lt;i&gt;Results:&lt;\/i&gt; Ninety-six patients, mean age 84 years, 65 females, 54% had neurological impairment. The initial dose of clobetasol propionate was 30 g\/day, followed by a progressive decrease. In the first 6 months, 14% were lost to follow-up and 17.7% died; 62% were controlled with topical steroids alone, and 25% had adjunctive systemic treatment. Difficulties of compliance were mentioned in 34.4%, without significant difference between controlled and noncontrolled patients. After 12 months, 23% were lost to follow-up and 27.1% died. The mean duration of the treatment was 11.7 \u00b1 8.4 months. After the stop, 18.9% of patients relapsed within 3 months. &lt;i&gt;Conclusion:&lt;\/i&gt; We emphasize the frequent recourse to systemic treatments in the first few months, the difficulties of compliance and of follow-up in our day-to-day experience.<\/jats:p>","DOI":"10.1159\/000324899","type":"journal-article","created":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T09:33:49Z","timestamp":1301045629000},"page":"176-179","source":"Crossref","is-referenced-by-count":16,"title":["Management of Bullous Pemphigoid with Topical Steroids in the Clinical Practice of a Single Center: Outcome at 6 and 12 Months"],"prefix":"10.1159","volume":"222","author":[{"given":"S.","family":"Ingen-Housz-Oro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Valeyrie-Allanore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ortonne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Roujeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Chosidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2011,3,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136%2Fbmj.a180"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001%2Farchderm.131.1.48"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007%2Fs12016-007-0030-y"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001%2Farchderm.134.9.1075"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159%2F000106574"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001%2Farchderm.136.4.521"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001%2Farchderm.141.6.691"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa011592"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038%2Fjid.2008.412"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2FS0190-9622%2899%2970156-8"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016%2FS0190-9622%2899%2970084-8"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001%2Farchderm.143.12.1536"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016%2FS0190-9622%2897%2970336-0"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038%2Fjid.2010.301"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/324899","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/324899","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:35:29Z","timestamp":1745436929000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000324899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":14,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,5,1]]},"published-print":{"date-parts":[[2011,5,3]]}},"URL":"https:\/\/doi.org\/10.1159\/000324899","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}